Sangamo Therapeutics, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alexander D. Macrae Ch.B
- Full Time Employees
- 127
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 501 Canal Blvd Richmond CA United States of America 94804
- IPO Date
- Apr 6, 2000
- CIK
- 0001001233
- Website
- sangamo.com
- Similar Companies
- Business
- Sangamo Therapeutics, Inc. (SGMO) is a clinical-stage genomic medicine company leveraging proprietary zinc finger protein technology for gene editing, gene therapy, gene regulation, epigenetic regulation and cell therapy to develop treatments for serious neurological diseases, rare genetic disorders and other conditions with high unmet needs; its core wholly owned pipeline includes ST-503, an epigenetic regulator delivered intrathecally for intractable pain due to idiopathic small fiber neuropathy (iSFN) with FDA IND clearance and planned Phase 1/2 dosing in mid-2025, ST-506 for prion disease using STAC-BBB capsid for intravenous delivery with CTA submission expected in Q1 2026, undisclosed neurology targets, isaralgagene civaparvovec (ST-920) AAV gene therapy in Phase 1/2 for Fabry disease with FDA-aligned accelerated approval pathway using eGFR slope data and potential BLA in H2 2025, and giroctocogene fitelparvovec (SB-525) for hemophilia A following regain of full rights from Pfizer in December 2024; partnered programs encompass neurology targets with Genentech (epigenetic regulation and STAC-BBB), Astellas (STAC-BBB for up to five targets), Eli Lilly (third capsid license), Alexion and Takeda; the STAC-BBB novel AAV capsid platform enables superior CNS penetration for intravenous genomic medicines. Founded in 1995 and headquartered in Brisbane, California, the company operates primarily in the United States with global partnerships extending its reach; it employs approximately 183 people and targets patients in neurology (neuropathic pain, prion disease, neurodegenerative disorders), Fabry disease, hemophilia A and immunology including organ transplant rejection via CAR-Treg therapies like TX200. Recent developments include neurology license agreements with Genentech in August 2024 and Astellas in December 2024 providing upfront fees and up to $1.3 billion in milestones plus royalties, a third STAC-BBB capsid deal with Eli Lilly potentially worth $1.4 billion, over $100 million in 2024 non-dilutive funding via licenses and milestones plus equity, FDA clearance for ST-503 IND, nonclinical prion disease proof-of-concept with survival extension in models, sustained Phase 1/2 Fabry data showing kidney function gains and ERT withdrawal in all patients, Pfizer's termination returning hemophilia A rights with data access for new partnerships, advanced Fabry partner negotiations, and 2024 operational restructuring halving non-GAAP expenses to focus on neurology while preparing Fabry BLA amid $41.9 million cash position as of year-end.
Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results